Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Basal cell carcinoma (BCC) is an epithelial tumour of the skin. It seldom metastasizes, but has the potential for local invasion and destruction. It usually occurs as one or several small pearly ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced CSCC, ...

Beyond CSCC, Libtayo is authorised to treat basal cell carcinoma, the most common type of skin cancer, as well as non-small cell lung cancer (NSCLC). Regeneron recently presented five-years results ...

According to precedent and due to his status, Yoon will probably be assigned a solitary cell, likely bigger and better appointed than the standard 6.56 square metre (71 square feet) single cells.

People taking metformin had a significantly lower risk of basal cell cancer and a significantly lower risk of squamous cell cancer, results show. “This study strengthens the evidence supporting ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...